Hyderabad: Indian company Dr. Reddy's Laboratories on Friday applied to the Drugs Controller General of India (DCGI) for permission to conduct phase-3 human clinical trials of Russian anti-coronavirus vaccine, 'Sputnik V', in India.
According to reports, the Hyderabad-based firm has applied to the DCGI seeking permission to conduct phase-3 human clinical trials of the Sputnik V vaccine against COVID-19 developed by Russia. The DCGI is expected to conduct a "technical evaluation" of the application before giving its go-ahead to the firm.
It needs mention here that the Hyderabad-based giant has collaborated with the Russian Direct Investment Fund (RDIF) in order to conduct clinical trials of the 'Sputnik V' that Russia has said is at an "advanced stage" of development. Even Russian President Vladimir Putin's daughter has been inoculated with this particular vaccine.
According to reports, the RDIF will supply 100 million doses of the vaccine to Dr. Reddy's once the approval is given.
Since September 1, Russia has been conducting the phase-3 trial of the Covid-19 vaccine 'Sputnik V' on nearly 40,000 subjects.
'Sputnik V', the Russian COVID-19 vaccine candidate, has been developed by the Gamaleya National Research Centre of Epidemiology and Microbiology and RDIF.
Two vaccine candidates in India - the one developed by Bharat Biotech in collaboration with ICMR and the one developed by Zydus Cadila Ltd - are in phase 2 of human clinical trials.